Clinical commissioning champion 'close to despair'
A clinical commissioning champion has found himself close to depression over the government’s proposed health reforms (Source: Management in Practice)
Vorapaxar Meets End Point But Ups Bleeding Vorapaxar Meets End Point But Ups Bleeding
In its second phase 3 trial, Merck's novel antiplatelet agent reduced ischemic events but increased bleeding, including ICH. Results looked more promising in patients without a history of stroke. Heartwire (Source: Medscape Today Headlines)
